Objectives: E-101 Solution (E-101) is a novel myeloperoxidase-mediated antimicrobial. It is composed of porcine myeloperoxidase (pMPO), glucose oxidase, glucose as the substrate and specific amino acids in an aqueous vehicle. E-101 is being developed for topical application directly into surgical wounds to prevent surgical site infections (SSIs). The in vitro activity of E-101 was investigated.
Introduction E-101 Solution (E-101) is a defined formulated cell-free oxidantgenerating enzyme system containing: (i) two therapeutic enzymes [porcine myeloperoxidase (pMPO) and glucose oxidase (GO)]; (ii) glucose, which is the substrate for GO; (iii) sodium chloride; and (iv) proprietary amino acids that enhance the activity of the system once it has been activated after mixing all of the components. The putative microbicidal mechanism of action of E-101 involves the binding of pMPO to the surface of target microorganisms where hypochlorous acid (HOCl) and singlet oxygen ( 1 O 2 ) exert direct oxidative damage. 1 -9 In the presence of hydrogen peroxide (H 2 O 2 ), generated in situ by GO from glucose and oxygen, the microorganismbound pMPO catalyses the oxidation of chloride ion to HOCl and facilitates the disproportionation of H 2 O 2 to 1 O 2 at or near the surface of the target organism ( Figure 1 ).
Myeloperoxidase (MPO) is a member of the family of highly conserved mammalian peroxidases and is found in high abundance in the azurophil granules in neutrophils. MPO is the principal haem protein of the neutrophil and is involved in the host defence mechanism against infection and is a key component of the oxygen-dependent antimicrobial system of the neutrophil phagosome. 10 The ability to efficiently kill phagocytized microbes requires the activities of membrane-bound nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) and MPO within the phagolysosome. The oxidase uses NADPH to reduce oxygen to generate the H 2 O 2 that drives the MPO-dependent oxidation of chloride, yielding HOCl and ultimately factors.
1,11 1 O 2 formed by HOCl-mediated oxidation of H 2 O 2 has been implicated as the principal bactericidal oxidant in the phagosome. 12 The highly electrophilic reactivity of 1 O 2 enables it to oxidize regions of high electron density in target biological molecules resulting in destruction of membrane integrity and/or the oxidative inhibition of the enzymes required for metabolic function.
E-101 is formulated to mimic the intrinsic functions of the phagolysosome in situ. It is stable and active when applied directly into a surgical incisional wound, which might be bloody (up to 27% erythrocytes by volume), contaminated by bacteria (up to 10 8 cfu/mL), viscous and acidic. E-101 is intended as a supplement to current standard-of-care measures to prevent surgical site infections (SSIs). Despite significant improvement in infection control practices (e.g. prophylactic systemic antibiotics), SSIs persist and are most frequently caused by aerobic Gram-positive (e.g. staphylococci, streptococci and enterococci) and/or Gram-negative (e.g. Enterobacteriaceae and non-Enterobacteriaceae) bacteria. 13 -15 A critical concern about SSIs is the escalating problem of antibiotic-resistant bacteria as causative agents. 16 E-101 has been developed specifically to deliver a potent, broad-spectrum, rapid-acting, microbicidal effect at the site of microbial contamination within the surgical wound, thereby reducing the risk of SSIs. There is no anticipated collateral damage to surrounding host cells and tissues by E-101 at concentrations proposed for clinical application because the microsecond lifetime of 1 O 2 , the proposed primary agent of microbial killing, restricts its radius of reactivity. 17 -19 This study was conducted to demonstrate the intrinsic antimicrobial properties of E-101 as a potential topical agent to prevent SSIs. Accordingly, MIC, MBC, time -kill, drug combination and resistance selection experiments were performed against a broad spectrum of aerobic pathogens.
Materials and methods

Bacterial isolates
A total of 530 bacterial strains were selected to determine the spectrum of activity of E-101 by MIC and MBC testing. The bacterial strains included: 140 staphylococci [including 70 methicillin-resistant, 4 confirmed Panton-Valentine leucocidin (PVL)-positive isolates and 5 vancomycin-intermediate Staphylococcus aureus/vancomycin-resistant S. aureus (VISA/VRSA)]; 95 b-haemolytic streptococci; 55 enterococci (33 were vancomycin susceptible and the remaining 22 were vancomycin resistant); 148 Enterobacteriaceae strains (51 were ceftazidime resistant); and 92 non-Enterobacteriaceae strains (54 were ceftazidime resistant). All clinical isolates were from the culture collection of Eurofins Medinet Anti-Infective Services (Chantilly, VA, USA). The strains were obtained from diverse geographical regions of North America and were originally isolated clinical specimens from symptomatic patients ( Table 1) . Escherichia coli ATCC 25922, S. aureus ATCC 25923, S. aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853 and Enterococcus faecalis ATCC 29212 were used as quality control strains for E-101 and to validate a new modified CLSI (formerly NCCLS) broth microdilution method described in this report.
Antimicrobial agents
E-101 is composed of two aqueous solutions designated as enzyme solution and substrate solution. They are packaged in two separate vials and mixed together to activate the system. The two stock solutions were prepared at AAI International (Charleston, SC, USA) and a range of concentrations of E-101 was prepared just prior to use. The enzyme solution contains pMPO, GO derived from Aspergillus niger and proprietary amino acids in an aqueous formulation vehicle consisting of 150 mM sodium chloride and 0.02% w/v polysorbate 80 in 20 mM sodium phosphate buffer pH 6.5. The stock concentrations of pMPO and GO were 1.2 mg/mL and 80 U/mL, respectively. The substrate solution contains 300 mM glucose in the same aqueous formulation as the enzyme solution. In this report, the concentration of E-101 is expressed only in terms of milligrams of pMPO per litre (mg pMPO/L) in the solution. The concentrations of GO and amino acids are directly proportional to pMPO (3: 1 MPO/GO ratio). The concentrations of the other components are held constant.
Quality control agents included cefazolin and gentamicin from Sigma Chemical Co. (St Louis, MO, USA) and mupirocin from GlaxoSmithKline, Inc. (Philadelphia, PA, USA). All stock solutions were prepared immediately prior to testing. The pMPO test concentrations were: 0.004-8 mg pMPO/L E-101; 0.06-64 mg/L cefazolin; 0.5-32 mg/L gentamicin; and 0.03-32 mg/L mupirocin. Antibiotics used for drug interaction studies included cefazolin, ceftriaxone, ceftazidime, ciprofloxacin, doxycycline, gentamicin, imipenem and vancomycin (GlaxoSmithKline, Inc.).
MIC determination
Broth microdilution and methods for determining bactericidal activity were performed using modifications to the CLSI-recommended procedures. 20, 21 Modifications were made to the standard broth microdilution method to accommodate the rapid in vitro activity of E-101. In the modified CLSI method, first the enzyme solution was diluted in Mueller-Hinton broth, resulting in doubling dilutions throughout the microdilution tray. Next, the bacterial suspension, prepared in the glucose substrate solution, was added to each well and mixed with the enzyme dilutions. This was done because of the rapidity of E-101 enzymatic reactions. Each antimicrobial agent and enzyme solution was diluted in double strength, cation-adjusted Mueller-Hinton broth (CAMHB) and dispensed in microdilution trays. All b-haemolytic streptococci were tested in double-strength CAMHB supplemented with 5% Denys et al.
lysed horse blood. Isolates were prepared by suspending several colonies (four to six) from an overnight culture on Trypticase soy agar (TSA) with 5% sheep blood in sterile saline and the density was adjusted to a turbidity equivalent to that of a 0.5 McFarland standard ( 10 8 cfu/mL). Standardized bacterial suspensions were further diluted in double-strength E-101 substrate solution previously described so that a suspension of 5×10 5 cfu/mL was mixed with serial drug dilutions. The microdilution trays were incubated in ambient air at 358C for 18-24 h. The MIC of E-101 was determined by observing the lowest concentration of antimicrobial agent that completely inhibited the growth of the organism and was expressed as mg pMPO/L. The MIC 50 and MIC 90 represent, respectively, the concentrations at which 50% and 90% of the isolates were inhibited.
MIC ranges were established for E-101 by testing .20 replicates of one lot of E-101 against S. aureus ATCC 29213 and E. coli ATCC 25922. Quality control parameters were then determined for E-101 by testing three different lots of the enzyme solution (pMPO and GO) used for preparation of the final E-101 formulation. Testing was performed in duplicate against S. aureus ATCC 29213 and E. coli ATCC 25922. The effects of modifying the standard broth microdilution test were also assessed with antibiotics with known quality control limits to validate the CLSI broth microdilution method. 22 
MBC determination
MBCs were determined by first using the modified broth microdilution method described above for E-101 MIC. From the microdilution tray, the last drug-containing well with visible growth and each clear well thereafter were sampled. A 10 mL sample from each well was plated onto TSA with 5% sheep blood, incubated in ambient air at 358C for 18-24 h and examined for growth and colony counts. The MBC was determined by observing the lowest antimicrobial concentration that demonstrated a ≥99.9% reduction in cfu relative to the number of cfu in the starting inoculum. The MBC 50 and MBC 90 represent, respectively, the concentrations at which 50% and 90% of the isolates were killed.
Time -kill assay
The bactericidal effect of E-101 was assessed by an adaptation of the CLSI microdilution time-kill assay. 21 Test organisms included S. aureus ATCC 29213, E. faecalis ATCC 29212, E. coli 25922 and P. aeruginosa ATCC 27853. Several colonies (four to six), grown on TSA with 5% sheep blood overnight, were suspended in 3 mL of deionized water and suspensions were adjusted to a turbidity equivalent to that of a 0.5 McFarland standard ( 1×10 8 cfu/mL). This suspension was then diluted 1 :10 in pre-warmed CAMHB and incubated for 1 -4 h in a shaker incubator at 378C. When the culture reached its logarithmic growth phase and the turbidity approximated that of a 0.5 McFarland standard, 100 mL was removed and added to 10 mL of E-101 substrate solution previously described to attain a final concentration of 5×10 6 cfu/mL. This suspension constituted the inoculum for the time-kill assay. The time-kill reaction wells contained 100 mL of enzyme solution prepared in CAMHB and inoculum (50 mL of enzyme solution and 50 mL of inoculum prepared in substrate solution). The final concentrations of pMPO in the enzyme solution were 16-fold dilutions of the highest concentration; 0, 0.06, 1, 16 and 256 mg pMPO/L. An identical reaction well containing broth and inoculum, but no enzyme solution, constituted the culture growth control. The final bacterial cell concentration was 5×10 5 cfu/mL. The microdilution trays were incubated at 358C in ambient air and 10 mL of a 1% catalase solution was added to each time-kill well at 0, 5, 15, 30 and 60 min and 4 h to stop the antimicrobial action of E-101. Serial samples were obtained for quantification. A 100 mL sample was removed from each well at each timepoint and serial dilutions were prepared in sterile saline.
A 100 mL volume of each dilution was applied to duplicate TSA plates with 5% sheep blood and spread over the surface with a sterile inoculating loop. The plates at time zero functioned as the purity plates. Following overnight incubation at 358C, colonies were manually counted and viable counts were calculated. The data are presented as log 10 reduction in cfu/mL at designated timepoints compared with the original cfu/mL at the start of testing. Bactericidal activity was defined as a 99.9% or a 3 log 10 cfu/mL reduction in the colony count from the initial inoculum.
Antimicrobial interactions
Three multidrug-resistant clinical strains were used to test for adverse interactions between E-101 and standard antibiotics by implementing a chequerboard titration method using 96-well microdilution trays. 23 The test organisms included VISA Mu50 (Network on Antimicrobial Resistance in S. aureus isolate NRS1), 24 E. coli (Eurofins 1075701) and P. aeruginosa (Eurofins 1445536). E-101 and selected antibiotics were tested by the broth microdilution method with CAMHB and serially diluted (2-fold) alone and in combination. Each well in the chequerboard contained a unique combination of the two drug concentrations and two rows contained one drug alone. Drug concentration ranges for E-101 were 0.0005-0.5 mg pMPO/L against S. aureus, 0.008-8 mg pMPO/L against E. coli and 0.001-1.0 mg pMPO/L against P. aeruginosa. Concentration ranges of all antibiotics were ≤0.25-2 times their respective MIC for the tested isolate. The inoculum, prepared in substrate solution as described above, was added to each well of the microdilution trays and incubated in ambient air at 358C. The MIC of each antimicrobial agent alone and in combination was defined as the lowest concentration(s) that demonstrated no visibly detectable growth after 18 -24 h. The fractional inhibitory concentration index (FICI) was interpreted as follows: ≤0.5, synergy; .0.5-4.0, no interaction; and .4.0, antagonism. 25 
Resistance selection
To determine whether repeated exposure of organisms to subinhibitory concentrations of E-101 resulted in the emergence of resistance, a serial passage method was used in microdilution trays. 26 Ten test strains included S. aureus (ATCC 29213 and Eurofins 1288199), E. faecalis (ATCC 29212 and ATCC 51299), E. coli (ATCC 25922, Eurofins 1075701, Eurofins 1337451 and Eurofins 1337019) and P. aeruginosa (ATCC 27853 and Eurofins 1077561). Baseline MICs of E-101 were determined as described above. Inocula for subsequent MIC tests were prepared from the well containing the highest concentration of E-101 that allowed growth. A fresh panel, containing E-101 serially diluted in CAMHB, was reinoculated with the new suspension prepared in substrate solution. Passages were continued for 21 consecutive days and E-101 MICs were determined following each serial passage. Subsequently, if the MICs showed an increase, stability studies were performed by three serial passages on drug-free agar (TSA) plates with new MICs being determined. In vitro activity of E-101 antibacterial solution 337 JAC vancomycin-resistant enterococci. E-101 was most active against the staphylococci. All MICs for S. aureus and Staphylococcus epidermidis strains, including methicillin-resistant S. aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) were ≤0.06 mg pMPO/L; the MIC 50 was ≤0.06 mg pMPO/L and the MIC 90 was 0.03 mg pMPO/L. E-101 was highly active against PVL-positive and VISA/VRSA strains, demonstrating equivalent activity compared with the wild-types. The range of E-101 MIC values for PVL-positive isolates was similar to that for all S. aureus strains tested. In contrast, the mupirocin MIC range for S. aureus and S. epidermidis strains was several-fold higher than the E-101 MIC range. Two S. aureus and 10 S. epidermidis strains yielded a mupirocin MIC of .32 mg/L, whereas the maximum E-101 MIC for these strains was 0.06 mg pMPO/L. For the streptococci, E-101 and mupirocin demonstrated similar MIC 90 s and ranges for Streptococcus agalactiae and Streptococcus pyogenes. There was, however, a clear trend of higher E-101 MIC for viridans Streptococcus groups C, F and G compared with the MIC for the other Grampositive and Gram-negative bacteria tested (see Table 1 ). This may reflect the added 5% lysed horse blood, which is rich in catalase and competitive substrates for oxidation.
Results
MIC and MBC determination
E-101 was highly active against the Enterobacteriaceae species (Table 1) with an MIC 90 of 0.25 mg pMPO/L and an MIC range of 0.03-0.25 mg pMPO/L. For the Gram-negative nonfermentative organisms, the MICs were ≤0.12 mg pMPO/L and displayed a narrow range of activity (≤0.004-0.12 mg pMPO/L). E-101 displayed excellent activity against bacteria difficult to eradicate, such as P. aeruginosa (MIC 90, 0.06 mg pMPO/L) and Acinetobacter baumannii (MIC 90 0.12 mg pMPO/L). No difference was noted in the activity of E-101 against ceftazidimesusceptible and ceftazidime-resistant strains. Based on the MIC 90 , E-101 was 32 to .256-fold more active than gentamicin against all Gram-negative organisms tested. E. faecalis vancomycin susceptible (n ¼27), E. faecalis vancomycin resistant (n ¼6). c E. faecium vancomycin susceptible (n¼6), E. faecium vancomycin resistant (n ¼16). d S. aureus methicillin susceptible (n¼55), MRSA (n¼45), VISA/VRSA (n ¼5), S. aureus PVL positive (n¼4). e S. epidermidis methicillin susceptible (n¼6), S. epidermidis methicillin resistant (n¼25). f CAMHB supplemented with 5% lysed horse blood was used for all streptococcal MIC studies. g C. freundii ceftazidime susceptible (n¼11), C. freundii ceftazidime resistant (n ¼9). h E. cloacae ceftazidime susceptible (n ¼11), E. cloacae ceftazidime resistant (n ¼10). i E. coli ceftazidime susceptible (n¼34), E. coli ceftazidime resistant (n¼18). j K. pneumoniae ceftazidime susceptible (n¼17). K. pneumoniae ceftazidime resistant (n ¼14). k A. baumannii ceftazidime susceptible (n¼11), A. baumannii ceftazidime resistant (n¼18). l P. aeruginosa ceftazidime susceptible (n ¼17), P. aeruginosa ceftazidime resistant (n¼36).
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MICs of cefazolin, gentamicin and mupirocin were compared between the standardized and modified CLSI reference broth microdilution methods. 20 The in vitro test parameters of both modified and reference MIC methods were similar in respect of medium (CAMHB), pH (7.2), final inoculum (5×10 5 cfu/L) and incubation environment (358C in ambient air). Cefazolin and mupirocin MICs for S. aureus ATCC 29213 and cefazolin and gentamicin MICs for E. coli ATCC 25922 were within previously published quality control ranges. 21 The quality control range determined for E-101 for S. aureus ATCC 29212 and E. coli ATCC 25922 was 0.01-0.03 mg pMPO/L and 0.15-0.5 mg pMPO/L, respectively. Replicate testing performed with these organisms and results of testing three different lots of enzyme solution demonstrated all MIC values to be within the established quality control range.
The MIC and MBC results are shown in Table 2 . The potent bactericidal activity of E-101 was confirmed by the range of MBCs (0.015-2 mg pMPO/L) against Gram-positive and Gramnegative clinical isolates. E-101 was most active against all isolates of S. aureus with an MIC to MBC ratio of 1 (MIC 50 and MBC 50 ¼ 0.015 mg pMPO/L; MIC 90 and MBC 90 ¼0.03 mg pMPO/L).
Bactericidal activity
The killing kinetics of E-101 are shown in Figure 2 . E-101 demonstrated bactericidal activity against S. aureus and P. aeruginosa at all concentrations tested. Against E. coli, E-101 was bactericidal at all concentrations tested except at 0.06 mg pMPO/L, which is 4-fold below its MIC. Against E. faecalis, E-101 was bactericidal at concentrations 32-fold above the MIC. The MICs for E. faecalis and P. aeruginosa were 0.5 and 0.06 mg pMPO/L, respectively. The rate of kill for all four bacterial strains was greater at higher concentrations of E-101 and the extent of kill increased with length of exposure time. Therefore, E-101 bactericidal activity under in vitro conditions was both concentration and time dependent. At E-101 concentrations of 256 and 16 mg pMPO/L, no detectable growth of all bacterial strains was observed within 30 min and 4 h, respectively. After 4 h of exposure to E-101, a .3 log 10 reduction was achieved at 0.06 mg pMPO/L for S. aureus and P. aeruginosa, at 1.0 mg pMPO/L for E. coli and at 16 mg pMPO/L for E. faecalis.
Antimicrobial interactions
Antimicrobial interaction studies of E-101 with cefazolin, ceftazidime, ceftriaxone, ciprofloxacin, doxycycline, gentamicin, imipenem and vancomycin were performed and generated five to six chequerboard combinations for each of the three test bacterial strains (Table 3 ). The combinations were tested in duplicate and were highly reproducible (within one doubling dilution). All FICIs were interpreted as no interaction for each antimicrobial combination.
Resistance selection
The MIC results for S. aureus, E. faecalis and P. aeruginosa remained within one doubling dilution after daily passage in subinhibitory concentrations of E-101 for 21 days (Table 4 ). The MICs for three clinical strains of E. coli showed an increase of four or more doubling dilutions after only one passage from day 1 to day 2, and the MICs remained elevated for 21 days. The change in MICs over the study interval was 0.12 to 8 mg pMPO/L, 0.25 to 8 mg pMPO/L and 0.5 to 8 mg pMPO/L for each strain, respectively. After three passages of each strain on drug-free agar plates, the MICs were not stable upon retesting and decreased back to two or fewer doubling dilutions of the initial baseline MIC.
Discussion
E-101 represents an MPO-mediated investigational product for killing microorganisms that may contaminate the surgical incision site. A number of studies have demonstrated that haloperoxidase/H 2 O 2 /halide systems are microbicidal in vitro against a variety of bacteria, 27 yeast, 8 viruses 28 and bacterial and fungal spores. 29 The susceptibility data presented in this study demonstrated the wide spectrum of activity of E-101 against clinically important antibiotic-susceptible and multidrugresistant bacteria, including those responsible for the majority In vitro activity of E-101 antibacterial solution 339 JAC of SSIs. E-101 had greater activity against the staphylococci than did mupirocin and equivalent to greater activity against aerobic Gram-negative bacteria than did gentamicin, which is considered the 'gold-standard' topical antibiotic for these bacteria. Furthermore, E-101 demonstrated bactericidal activity against S. aureus and S. pyogenes (Table 2) , two of the most common causative pathogens of SSIs. 30, 31 Historically, tolerance has primarily been associated with b-lactam agents. The generally accepted definition of tolerance is a ratio of the MBC to the MIC of .32. 32 This study showed that the MBC to MIC ratio for E-101 was 1-2, indicating no evidence of E-101 antimicrobial tolerance.
Time-kill kinetic studies further demonstrated clearly the bactericidal nature of E-101 in a concentration -dependent manner. The FICIs were interpreted as follows: ≤0.5¼synergy; .0.5-4 ¼no interaction (NI); and .4.0¼antagonism.
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